



## Global offering of DBV Technologies ordinary shares

### Over-allotment option exercised in full

**Bagneux, France – October 23, 2014** – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), a clinical-stage specialty biopharmaceutical company announced today that the underwriters in its recently announced global offering have exercised in full their options to purchase an additional 401,045 ordinary shares in the global offering, of which 320,836 ordinary shares in the form of 641,672 American Depositary Shares, or ADSs, are to be purchased in the underwritten public offering in the United States, Canada and countries outside of France and 80,209 ordinary shares are to be purchased in the concurrent registered private placement through international underwriters in France and countries outside of the United States and Canada. The settlement of the new shares is expected to occur on October 24, 2014.

Citigroup Global Markets Inc., Leerink Partners LLC and Bryan, Garnier & Co. are acting as joint global coordinators and joint book-running managers of the global offering. Citigroup Global Markets Inc. and Leerink Partners LLC are acting as representatives of the U.S. underwriters. Citigroup Global Markets Limited is acting as representative of the international underwriters. The U.S. underwriters are Citigroup Global Markets Inc., Leerink Partners LLC, Bryan, Garnier & Co and Trout Capital LLC. The international underwriters are Citigroup Global Markets Limited and Bryan, Garnier & Co.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 21, 2014. When available, copies of the final prospectus relating to the offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 1-800-831-9146; email: [prospectus@citi.com](mailto:prospectus@citi.com); Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37<sup>th</sup> Floor, Boston, MA 02110, telephone: 1-800-808-7525 ext. 6142; email: [Syndicate@Leerink.com](mailto:Syndicate@Leerink.com); and Bryan, Garnier & Co., Attention: Prospectus Department, 26 Avenue des Champs-Élysées, 75008 Paris France, telephone: +33 1 56 68 75 20; email: [prospectus@bryangarnier.com](mailto:prospectus@bryangarnier.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the securities note (*note d'opération*) which received visa n°14-564 from the AMF on October 22, 2014 and copies of the Reference Document registered by the AMF on April 16, 2014 under No. 14-017 and its update filed with the AMF on September 22, 2014 under No. D.14-0286-A01 are available free of charge at DBV Technologies' head office in Green Square, 80/84 rue des Meuniers - 92220 Bagneux - France, and on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)).

## About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure.

DBV Technologies ordinary shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: [www.dbv-technologies.com](http://www.dbv-technologies.com).

## Forward Looking Statements

This press release contains forward-looking statements, including statements about the proposed timing of the global offering. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers and the Registration Statement filed with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

## DBV Technologies Contacts

### David Schilansky

Chief Financial Officer

Tel. : +33(0)1 55 42 78 78

[david.schilansky@dbv-technologies.com](mailto:david.schilansky@dbv-technologies.com)

### Susanna Mesa

VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447

[susanna.mesa@dbv-technologies.com](mailto:susanna.mesa@dbv-technologies.com)

### Nathalie Donne

Director, Corporate Communication & Business Development

Tel. : +33(0)1 55 42 78 78

[nathalie.donne@dbv-technologies.com](mailto:nathalie.donne@dbv-technologies.com)

## DBV IR and Media Contacts

### The Trout Group

U.S. Investor Relations

Todd James

Tel. : +1 646-378-2926

[tjames@troutgroup.com](mailto:tjames@troutgroup.com)

### Rooney & Associates

Media Relations

Marion Janic

Tel. : +1-212-223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)